Prevention of Elevation in Plasma Triacylglycerol with High-Dose Bezafibrate Treatment Abolishes Insulin Resistance and Attenuates Glucose Intolerance Induced by Short-Term Treatment with Dexamethasone in Rats

Figure 4

Glucose tolerance and insulin sensitivity. (a) The average blood glucose values during an intraperitoneal glucose tolerance test (ipGTT) (2 g/kg, body mass), (b) the average values of area under curve (AUC), and (c) the plasma insulin in response to glucose load. Bezafibrate treatment attenuated the glucose intolerance caused by the dexamethasone treatment in the BezaDexa group. (d) The average of normalized blood glucose values (as % from min 0) during an intraperitoneal insulin tolerance test (ipITT) (2 IU/kg, body mass) and (e) the respective constant for glucose disappearance (). Bezafibrate treatment prevented the insulin resistance caused by the dexamethasone treatment in the BezaDexa group. Results are expressed as mean ± SEM in (a, c, and d) and as mean ± SD in (b) and (e). In (a, c, and d), the variances were expressed as standard error of the mean (SEM) for esthetic reasons. Significantly different vs. the respective control group (dexamethasone effect) and ^#significantly different vs. the respective control group (bezafibrate effect) using two-way ANOVA with Tukey’s post hoc test. –8, .